Dr. Martin on Potential for CAR T-Cell Therapy in MCL Landscape
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the landscape of mantle cell lymphoma (MCL).
Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the landscape of mantle cell lymphoma (MCL).
CAR T-cell therapies and active immunotherapies are attractive in MCL because they offer a potentially curative approach, Martin explains. Similar to how allogenic stem cell transplant offers a curative approach, CAR T-cell therapy can potentially cure MCL, he adds.
The ongoing ZUMA-2 trial is evaluating anti-CD19 CAR T-cell therapy in patients following ibrutinib (Imbruvica) failure. If that is shown to be feasible, the therapy will likely be moved up in treatment settings for younger, higher-risk patients.
